C4 Therapeutics, Inc. Is This the Best Biotech Penny Stock to Buy Now - Yahoo Finance UK
CCCC Stock | USD 4.55 0.36 8.59% |
About 60% of all C4 Therapeutics' shareholders are looking to take a long position. The analysis of the overall investor sentiment regarding C4 Therapeutics suggests that some traders are interested. The current market sentiment, together with C4 Therapeutics' historical and current headlines, can help investors time the market. In addition, many technical investors use C4 Therapeutics stock news signals to limit their universe of possible portfolio assets.
CCCC |
C4 Therapeutics, Inc. Is This the Best Biotech Penny Stock to Buy Now Yahoo Finance UK
Read at news.google.com
C4 Therapeutics Investor Sentiment by Other News Outlets
Investor sentiment, mood or attitude towards C4 Therapeutics can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
C4 Therapeutics Fundamental Analysis
We analyze C4 Therapeutics' financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of C4 Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of C4 Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Short Ratio
Short Ratio Comparative Analysis
C4 Therapeutics is currently under evaluation in short ratio category among its peers. Short Ratio is typically used by traders and speculators to identify trends in current market sentiment for a particular equity instrument. In its simple terms this ratio shows how many days it will take all current short sellers to cover their positions if the price of a stock begins to rise.
C4 Therapeutics Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with C4 Therapeutics stock to make a market-neutral strategy. Peer analysis of C4 Therapeutics could also be used in its relative valuation, which is a method of valuing C4 Therapeutics by comparing valuation metrics with similar companies.
Peers
C4 Therapeutics Related Equities
GLUE | Monte Rosa | 13.72 | ||||
PRLD | Prelude Therapeutics | 7.14 | ||||
IPSC | Century Therapeutics | 5.52 | ||||
NRIX | Nurix Therapeutics | 4.15 | ||||
ARVN | Arvinas | 2.85 | ||||
CGEM | Cullinan Oncology | 2.75 | ||||
FHTX | Foghorn Therapeutics | 2.57 | ||||
EWTX | Edgewise Therapeutics | 2.48 | ||||
RZLT | Rezolute | 1.00 | ||||
STTK | Shattuck Labs | 0.92 | ||||
KYMR | Kymera Therapeutics | 0.02 | ||||
RVMD | Revolution Medicines | 1.25 | ||||
ELYM | Eliem Therapeutics | 1.30 | ||||
MLYS | Mineralys Therapeutics, | 2.59 |
Complementary Tools for CCCC Stock analysis
When running C4 Therapeutics' price analysis, check to measure C4 Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy C4 Therapeutics is operating at the current time. Most of C4 Therapeutics' value examination focuses on studying past and present price action to predict the probability of C4 Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move C4 Therapeutics' price. Additionally, you may evaluate how the addition of C4 Therapeutics to your portfolios can decrease your overall portfolio volatility.
Stocks Directory Find actively traded stocks across global markets | |
Portfolio Manager State of the art Portfolio Manager to monitor and improve performance of your invested capital | |
Portfolio Dashboard Portfolio dashboard that provides centralized access to all your investments | |
Pair Correlation Compare performance and examine fundamental relationship between any two equity instruments | |
Portfolio Rebalancing Analyze risk-adjusted returns against different time horizons to find asset-allocation targets | |
Aroon Oscillator Analyze current equity momentum using Aroon Oscillator and other momentum ratios | |
Portfolio Analyzer Portfolio analysis module that provides access to portfolio diagnostics and optimization engine | |
Piotroski F Score Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals | |
My Watchlist Analysis Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like |